ArticleCancer immunology, immunotherapy : CII2021
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Ayaka Hara et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it